Medicare Part D Negotiation and GLP-1 Drugs, Explained
Medicare's drug price negotiation authority is new, statutorily limited, and doesn't automatically apply to every high-profile drug. Here's the actual legal structure.
By the GLP Semaglutide editorial team · Last updated March 28, 2026
The Inflation Reduction Act created Medicare's first drug price negotiation authority, applying to a limited, expanding list of drugs selected each year based on total Medicare Part D spending and other statutory criteria.
Selection isn't automatic or immediate
A drug generally needs to have been FDA-approved for a minimum number of years and meet spending thresholds before it's eligible for selection, and negotiated prices phase in over a multi-year schedule after selection — meaning news of 'negotiation' for a given drug doesn't always mean an immediate price change.
Where to check current status
CMS publishes the official list of selected drugs and negotiated prices as they're finalized each cycle — the authoritative source for whether and when this applies to a specific GLP-1 product.
Primary sources